Previous close | 2.7518 |
Open | 2.7900 |
Bid | 0.0000 x N/A |
Ask | 0.0000 x N/A |
Day's range | 2.7900 - 2.7900 |
52-week range | 2.7900 - 2.7900 |
Volume | |
Avg. volume | N/A |
Market cap | 779,445 |
Beta (5Y monthly) | 1.19 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.8080 |
Earnings date | 29 Mar 2023 - 03 Apr 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Sino Biopharmaceutical, through its wholly-owned subsidiary, is set to acquire F-star (FSTX) for $7.12 per share in cash. The transaction is likely to close by second-half 2022.
Based on briefing documents issued by the FDA, a positive regulatory approval is expected on bluebird bio's (BLUE) gene-therapy for treating thalassemia.
Data from a late-stage study shows that AstraZeneca's (AZN) Enhertu meets superior and clinically meaningful progression-free survival and overall survival in HER2-low metastatic breast cancer patients.